Can I Take Vitamin B6 with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and Why Does It Matter for Supplement Safety?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, Evenity simultaneously increases bone formation and decreases bone resorption, a dual effect no other approved osteoporosis agent achieves. The FDA approved romosozumab in April 2019 for postmenopausal women with severe osteoporosis at high fracture risk [1].

The standard regimen is 210 mg delivered as two subcutaneous injections of 105 mg each, given once monthly for 12 consecutive months. After those 12 months, patients transition to an antiresorptive agent such as denosumab or a bisphosphonate to preserve the gains in bone mineral density (BMD).

Why Supplement Interactions Deserve Attention on Evenity

The Evenity prescribing label carries a boxed warning for serious cardiovascular events, including myocardial infarction and stroke, based on data from the ARCH trial (N=4,093), where romosozumab produced a higher rate of serious CV events compared with alendronate (2.5% vs. 1.9%) [2]. Patients on Evenity are therefore often managing multiple comorbidities and taking multiple supplements.

How the FDA Classifies Romosozumab's Elimination

Romosozumab is a large-molecule biologic eliminated through proteolytic catabolism, the same route as endogenous immunoglobulins. It does not pass through hepatic cytochrome P450 (CYP450) enzymes or renal tubular transporters that govern small-molecule drug and supplement interactions [1]. This biology-level distinction matters when evaluating supplement safety.

How Does Vitamin B6 Work in the Body?

Vitamin B6 is a collective name for three naturally occurring compounds: pyridoxine, pyridoxal, and pyridoxamine, plus their phosphorylated forms. The metabolically active coenzyme form is pyridoxal 5'-phosphate (PLP). PLP participates in over 100 enzymatic reactions involving amino acid metabolism, neurotransmitter synthesis, glycogenolysis, and one-carbon metabolism [3].

Absorption, Distribution, and Elimination of B6

Pyridoxine is absorbed in the jejunum via passive diffusion at normal dietary doses, converted to PLP primarily in the liver, and excreted renally as 4-pyridoxic acid [3]. Elimination half-life of PLP in plasma is approximately 25 days at tissue-saturating doses. None of these steps involve sclerostin, osteocyte signaling, or the Fc neonatal receptor (FcRn) recycling pathway that governs monoclonal antibody half-life.

Recommended Dietary Allowances for B6

The National Institutes of Health Office of Dietary Supplements sets the RDA at 1.3 mg per day for adults aged 19 to 50, rising to 1.5 mg for women over 50 [4]. The tolerable upper intake level (UL) is 100 mg per day from all sources combined. Sensory and peripheral neuropathy have been documented at sustained intakes above 200 mg per day, and case reports exist as low as 100 mg per day with prolonged use [5].

Is There a Direct Pharmacokinetic Interaction Between B6 and Romosozumab?

No direct pharmacokinetic interaction exists. Romosozumab is a 188-kilodalton IgG2 monoclonal antibody that bypasses the small-molecule hepatic and renal elimination routes entirely [1]. Pyridoxine is a 169-dalton water-soluble vitamin processed through hepatic phosphorylation and renal excretion [3]. The two compounds operate in completely separate pharmacokinetic compartments.

CYP450 and Transporter Considerations

CYP450 inhibition or induction is the most common mechanism behind clinically relevant drug-supplement interactions. Pyridoxine at dietary doses does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [6]. Because romosozumab itself is not a CYP substrate, even a theoretical CYP interaction would have no consequence here.

Protein Binding

Plasma protein binding is another classic conflict point. PLP binds albumin at approximately 50% [3]. Romosozumab binds sclerostin, not albumin, and its free-fraction pharmacokinetics are independent of albumin competition [1]. No displacement interaction is possible through this pathway.

Is There a Pharmacodynamic Interaction Between B6 and Romosozumab?

Pharmacodynamic interactions occur when two agents affect the same biological target or pathway in an additive, synergistic, or antagonistic manner. No evidence from clinical trials, case reports, or mechanistic studies suggests B6 modulates sclerostin levels, osteocyte function, or Wnt signaling, the pathway romosozumab activates downstream of sclerostin inhibition [7].

B6 and Bone Metabolism: What the Evidence Shows

B6 does have a biological relationship with bone, though it is indirect. PLP is a cofactor for lysyl oxidase, the enzyme that cross-links collagen fibrils in bone matrix [8]. Severe B6 deficiency in animal models impairs collagen cross-linking and reduces bone strength. However, the clinically relevant question is whether supplemental B6 at typical doses (1 to 50 mg/day) meaningfully alters bone remodeling in humans on romosozumab. No published randomized trial has tested this combination directly, and no mechanistic rationale supports a clinically important interaction at standard supplement doses.

Homocysteine, Cardiovascular Risk, and the Evenity Boxed Warning

This is the one area where B6 and romosozumab overlap in clinical relevance, though not through a direct interaction. Elevated homocysteine is an independent cardiovascular risk marker [9]. Romosozumab already carries a boxed warning for serious CV events [2]. B6, along with folate and B12, lowers plasma homocysteine by supporting the transsulfuration pathway [10].

The clinical implication: a patient on Evenity who also has elevated homocysteine may actually benefit from ensuring adequate B6, folate, and B12 intake as part of broader cardiovascular risk management. Prescribers managing the Evenity CV warning should already be assessing homocysteine in high-risk patients, per the 2023 American Heart Association scientific statement on cardiovascular risk in osteoporosis management [11].

What Doses of B6 Are Safe Alongside Evenity?

The NIH UL of 100 mg per day represents the evidence-based ceiling for long-term safety in the general population [4]. For patients on Evenity specifically, no dose adjustment to B6 is required on the basis of a pharmacological interaction. The risk ceiling is set by B6 neurotoxicity, not by any romosozumab-specific concern.

Standard Supplement Doses (Low Risk)

Most over-the-counter multivitamins contain 1.5 to 10 mg of pyridoxine per serving. B-complex supplements typically provide 25 to 50 mg. These ranges sit well below the 100 mg UL and carry no meaningful safety concern alongside romosozumab [4].

High-Dose B6 (Above 100 mg/day): Independent Risk

High-dose pyridoxine, often sold as 100 mg, 250 mg, or 500 mg single-ingredient capsules, carries a dose-dependent risk of sensory peripheral neuropathy and, at extreme doses, ataxia [5]. A 2023 systematic review in the European Journal of Nutrition (N=36 case series and cohort studies) found that the lowest reported dose associated with peripheral neuropathy onset was approximately 100 mg/day taken for more than 6 months [5]. The FDA issued a 2024 safety communication recommending that OTC B6 supplements remain below 100 mg per dose [12].

Patients should not take high-dose B6 during Evenity treatment, or at any other time, without a clinician-documented reason such as pyridoxine-responsive sideroblastic anemia or management of isoniazid-induced neuropathy.

Timing and Separation Windows

Because no pharmacokinetic interaction exists, there is no evidence-based requirement for dose-separation timing between B6 and romosozumab injections. Patients can take a B6-containing supplement on the same day as their monthly Evenity injection without concern.

What Does the Evenity Prescribing Label Say About Supplements?

The FDA-approved Evenity prescribing information does not specifically mention vitamin B6 or pyridoxine [1]. The label does require that patients receive adequate calcium and vitamin D during treatment, specifically, 1,000 mg elemental calcium per day and 800 IU vitamin D per day at minimum, adjusted for baseline serum levels.

Calcium and Vitamin D Are the Priority Supplements on Evenity

The Evenity label warns that hypocalcemia must be corrected before starting treatment, and that pre-existing severe renal impairment (eGFR <30 mL/min) requires careful calcium monitoring [1]. A 2022 analysis of the FRAME trial (N=7,180) found that romosozumab produced a 73% reduction in new vertebral fracture risk at 12 months compared with placebo, with this benefit contingent on adequate calcium and vitamin D status [13]. B6 does not influence calcium absorption or vitamin D metabolism.

Clinical Monitoring Recommendations During Evenity Treatment

The standard monitoring protocol during Evenity treatment includes serum calcium before each injection, renal function assessment at baseline and as clinically indicated, and periodic bone turnover marker measurements to confirm therapeutic response [1].

Should B6 Levels Be Monitored?

Routine serum PLP monitoring is not indicated for patients taking standard B6 supplements alongside Evenity. If a patient is taking high-dose B6 (above 100 mg/day) for a documented clinical reason, baseline and periodic neurological assessment, including evaluation for sensory changes in the hands and feet, is appropriate per standard high-dose B6 monitoring practice, independent of romosozumab [5].

Drug-Supplement Disclosure at Each Evenity Visit

The American College of Rheumatology and the National Osteoporosis Foundation both recommend that clinicians collect a full supplement and over-the-counter medication inventory at every osteoporosis management visit [14]. This practice identifies potential interactions earlier and documents baseline supplement exposure if adverse effects emerge. Patients should bring all supplement bottles to each monthly Evenity appointment.

What Other Supplements Require More Caution on Evenity?

B6 is among the lower-risk supplements on Evenity. Certain other common supplements warrant more careful evaluation.

Iron and Calcium Timing

Calcium supplements taken within 2 hours of oral bisphosphonates reduce absorption, but this timing concern does not apply to romosozumab because Evenity is delivered subcutaneously, bypassing GI absorption entirely [1].

St. John's Wort

St. John's Wort is a potent CYP3A4 inducer and P-glycoprotein inducer. It does not interact with romosozumab through these pathways for the same reason B6 does not, biologic monoclonal antibodies are not CYP substrates [6]. St. John's Wort may still affect other medications the patient takes, so it warrants disclosure.

Strontium

High-dose strontium supplements falsely raise DEXA-measured BMD values by substituting strontium for calcium in hydroxyapatite [15]. Patients on Evenity undergo serial DEXA scans to assess treatment response. Taking strontium supplements could lead to overestimation of BMD gains and should be avoided.

What the Evidence Shows for Romosozumab's Clinical Effectiveness

Understanding the therapeutic stakes of Evenity helps patients appreciate why adherence and supplement safety matter.

FRAME Trial Results

In the FRAME trial (N=7,180), romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% compared with placebo (P<0.001) at 12 months, and reduced clinical fractures by 36% (P<0.001) [13]. Lumbar spine BMD increased by 13.3% and total hip BMD by 6.9% at 12 months.

ARCH Trial Results

In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months (P<0.001) [2]. The same trial identified the CV signal that now appears in the boxed warning, with serious CV events occurring in 2.5% of the romosozumab group vs. 1.9% in the alendronate group.

STRUCTURE Trial Results

In the STRUCTURE trial (N=436), patients who had been on teriparatide switched to romosozumab and showed significantly greater gains in total hip BMD compared with patients who continued teriparatide (P<0.001 at 12 months) [16]. This trial confirmed that romosozumab's bone-forming effect is additive beyond prior anabolic therapy.

Practical Guidance: B6 and Evenity Together

Patients taking a standard B-vitamin supplement or multivitamin containing up to 50 mg of pyridoxine daily do not need to discontinue B6 or adjust its timing around Evenity injections. The combination is pharmacologically safe at normal supplement doses based on the entirely separate mechanisms of action and elimination pathways for both agents.

Patients who believe they need high-dose B6 (above 100 mg/day) should discuss this with their prescribing clinician before starting, not because of a romosozumab-specific risk but because of the independent peripheral neuropathy risk at those doses.

Any new neurological symptom, tingling, numbness, or balance changes, during combined use should be reported promptly, as the differential includes both high-dose B6 neuropathy and unrelated neurological conditions, and early evaluation improves outcomes regardless of cause [5].

At each monthly Evenity injection appointment, confirm with your provider that your current B6 dose, calcium intake, and vitamin D status remain appropriate. The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "Adequate calcium and vitamin D intake should be ensured in all patients receiving pharmacological therapy for osteoporosis, and all over-the-counter supplements should be disclosed to the treating clinician at every visit" [17].